| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:10746939 | IVTH | 0.000001 - 0.0001 M | 0.00003 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:17520059 | IVTH | 0.00001 M | 0.00001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:20381603 | IVR | 50 mg/kg | 50 mg/kg | Decreased prolactin levels | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg | 50 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Increased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Decreased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 12.5 mg/kg | 12.5 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:25461544 | IVTH | 0.000000000001 - 0.000001 M | 0.000000000003 - 0.000000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 0.005 mg/kg | 0.005 mg/kg | Increased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg | 0.005 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg | 0.005 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | - | No significant effects observed | - | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.